在新选项卡中打开链接
  1. Copilot 答案
    Nature
    https://www.nature.com › articles

    ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

    • Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells from donors has many potentia… 展开

    Introduction

    One of the most promising approaches in anticancer therapy is chimeric antigen receptor (CAR) T cell therapy, in which T cells are redirected against the tumour after engineered expr… 展开

    Nature
    Allogeneic CAR T cells sources

    The T cells currently used for CAR-T cell manufacturing are mainly derived from peripheral blood mononuclear cells (PBMCs) and, rarely, from umbilical cord blood (UCB). In … 展开

    Nature
    Approaches to avoid GVHD

    Potential risks associated with allogeneic cell therapy have been demonstrated in the context of allogeneic SCT. HLA mismatches between donor and recipient trigger immune r… 展开

    Nature
    Off-the-shelf CAR-T cells could prove paradigm shifting ... - Cell Press
    Cell Press
    Are allogeneic chimeric antigen receptor (CAR) T cells suitable for multiple patients?
    Off-the-shelf allogeneic CAR T cells may also allow combination of CAR T cells directed against different targets (Table 1). Fig. 1: Manufacturing of allogeneic CAR T cells. Allogeneic chimeric antigen receptor (CAR) T cells from a single manufacturing batch have the potential to benefit multiple patients.
    nature.com